The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

The Senate has confirmed Dr Jay Bhattacharya as the new director of the NIH and Dr Marty Makary as the new commissioner of the FDA.

Partial nephrectomy provides the best survival rates among treatment options in patients aged 75 years or older with T1-T2 renal cell carcinoma (RCC), according to research presented at the 40th ...

More than 3.8 million US lung cancer deaths were averted during 1970-2022 due to tobacco control, researchers say.

Clinical guidelines should establish clear timelines, and health care systems should prioritize timely treatment initiation and completion,” researchers concluded.

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

Biomarker testing in advanced NSCLC has increased in recent years, but turnaround time has remained roughly the same, data suggest.

In a survey last year by the American Medical Association, 93% of doctors said that insurers’ prior authorization practices ...

The FDA has approved Imfinzi (durvalumab) as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer.

Patients with metastatic NSCLC may benefit from continuing on pembrolizumab-based treatment after progressing on that ...

Some patients with locally advanced esophageal cancer may be able to safely forgo esophagectomy after CRT, data suggest.

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.